BioMarin Pharmaceuticals (BMRN) Q1 2024 Earnings
BMRN·Reported April 24, 2024·After market close
BioMarin Pharmaceuticals reported Q1 2024 revenue of $648.8M, missed analyst consensus of $651.8M by $3.0M. Diluted EPS came in at $0.71, beat the $0.31 consensus by $0.40.
Revenue
$648.8Mmissed by $3.0M
Consensus: $651.8MDiluted EPS
$0.71beat by $0.40
Consensus: $0.31
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about BioMarin Pharmaceuticals's Q1 2024 earnings report.
BioMarin Pharmaceuticals (BMRN) reported Q1 2024 earnings on April 24, 2024 after market close.
BioMarin Pharmaceuticals reported revenue of $648.8M and diluted EPS of $0.71 for Q1 2024.
Revenue missed the consensus estimate of $651.8M by $3.0M. EPS beat the consensus estimate of $0.31 by $0.40.
You can read the 10-Q periodic report (0001048477-24-000070) directly on SEC EDGAR. The filing index links above go to sec.gov.